Neogen Chemicals Ltd. · NSE:NEOGEN
Neogen Chemicals — Q4 FY2020 Earnings Presentation
18 slides from Neogen Chemicals's earnings presentation, May 24, 2020
Slide 1: Neogen Chemicals Ltd. Q4 & FY20 Earnings Presentation
Neogen Chemicals Ltd. Q4 & FY20 Earnings Presentation May 2020 )( .~. NEOGEN ~ CHEMICALS LTD. J<..
Slide 2: Safe Harbour
Safe Harbour 2 Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ
Slide 3: Table of Contents
Table of Contents 3 4 6 7 14 15 16 17 30 Introduction Q4 & FY20 Historical Competitive Management Way to Neogen Financial Financial Contact Us Advantages Commentary Forward Chemicals Performance Trends
Slide 4: Neogen Chemicals – At a Glance
Neogen Chemicals – At a Glance 4 Leading manufacturer of Bromine and Lithium-based specialty chemicals, operating since 1991 205 10°/o Products developed Of workforce in Strong portfolio of Organic and Inorganic products by in-house R&D R&D team Customers across multiple industries including Pharma,
Slide 5: Business Overview and Clientele
Business Overview 5 Organic Chemicals Inorganic Chemicals The portfolio includes specialty, inorganic Custom Synthesis & lithium-based chemical products which Bromine Compounds Advanced Intermediates Manufacturing find applications across multiple industries Organic compounds containing Combining br
Slide 6: Competitive Advantages
Competitive Advantages 6 Large and diverse array of products Strong Manufacturing Capabilities Experienced promoters with domain knowledge Diversified and Stable Established and stable Customer Base relationship with suppliers Specialised Business Model Continuous Investment with high entry barriers
Slide 7: Key Performance Highlights – Q4 & FY20
Key Performance Highlights – Q4 & FY20 7 FY20 Q4 FY20 Rs. 306 cr 0 28% Rs. 82 cr 0 3% FY20 Revenue Revenues break-up Rs. 58 cr 0 34% Rs. 16 cr 0 3% 36% 64% EBITDA Rs. 41 cr 0 40% Rs. 11 cr 0 8% Profit Before Tax Domestic *Exports Rs. 29 cr 0 37% Rs. 7 cr 0 16% *Including deemed exports Profit After
Slide 8: Financial Summary – FY2020
Financial Summary – FY2020 8 REVENUE EBITDA PAT 306.1 58.1 28.8 239.1 I• 43.4 21.0 •• FY19 FY20 FY19 FY20 FY19 FY20 Rs. crore Rs. crore Rs. crore • Trajectory in FY20 EBITDA sustained its remained robust barring momentum despite setback lockdown impact towards caused by CoVID-19 pandemic, the end of
Slide 9: Revenue break-up
Revenue break-up 9 Q4 FY20 Q4 FY19 FY20 FY19 2% Rs. 67 cr. Rs. 66 cr. 30% Rs. 249 cr. Rs. 192 cr. Organic Chemicals 14% Rs. 16 cr. Rs. 14 cr. 21% Rs. 57 cr. Rs. 47 cr. Inorganic Chemicals
Slide 10: Impact of CoVID-19 pandemic on business operations
Impact of CoVID-19 pandemic on business operations 10 • To contain the spread of CoVID-19 and in compliance with the directives of Government of India, the Company decided to temporarily close/partially close the manufacturing operations at the plants in Mahape (Navi Mumbai), Karakhadi (Vadodara) an
Slide 11: Seasonal Variance Factors
Seasonal Variance Factors 11 • Neogen’s business has some seasonal drivers, due to which the company tends to deliver stronger financial performance in the second half of the financial year (October to March). Seasonal variance is driven by strong demand from Europe as orders tend to scale up in Oct
Slide 12: Financial Table – Profit & Loss Statement (Standalone)
Financial Table – Profit & Loss Statement (Standalone) 12 Particulars (Rs. crore) Q4 FY20 Q4 FY19 Growth (%) FY20 FY19 Growth (%) Revenue 82.3 79.8 3.1% 306.1 239.1 28.1% Expenditure 66.5 63.5 4.7% 248.1 195.6 26.8% EBITDA 15.8 16.3 -3.0% 58.1 43.4 33.7% Margins 19.2% 20.4% 19.0% 18.2% Depreciation
Slide 13: Balance Sheet – Snapshot (Standalone)
Balance Sheet – Snapshot (Standalone) 13 Particulars (In Rs. crore) As on March 31, 2020 As on Sept 30, 2019 As on March 31, 2019 Assets Non-current assets 123.6 102.4 86.6 Current assets 231.7 194.5 160.1 Total Assets 355.3 296.9 246.7 Liabilities Shareholder’s Funds 156.7 141.6 70.5 Non-current Li
Slide 14: Management Commentary
Management Commentary 14 Commenting on the Q4 & FY20 performance, Mr. Haridas Kanani, Chairman & Managing Director, at Neogen Chemicals said: “I am pleased to share that we concluded our first full financial year post listing with healthy topline and PAT growth of 28% and 37% respectively. The perfo
Slide 15: Historical Financial Trends
Historical Financial Trends 15 Net Revenue from Operations** EBITDA (INR crore) Margin (%) (INR crore) 18.1% 17.8% 18.2% 19.0% 15.0% 14.0% 306 239 163 85 101 111 13 14 20 29 43 58 FY15 FY16 FY17 FY18 FY19 FY20 FY15 FY16 FY17 FY18 FY19 FY20 ** Revenue is Net of Excise PAT (INR crore) Margin (%) Netwo
Slide 16: Way Forward
Way Forward 16 Increasing Custom Synthesis & Manufacturing portfolio Augmenting growth in domestic and global markets Expanding production capacities Focus on advanced speciality intermediates Focus on operational efficiency and functional excellence
Slide 17: Contact Us
Contact Us 17 About Neogen Chemicals Limited For further information, please contact: Incorporated in 1989, Neogen Chemicals Ltd. (NSE Code: NEOGEN; BSE Code: 542665) is one of India’s leading manufacturers of Bromine-based and Mahesh Tanna Lithium-based specialty chemicals. Its specialty chemicals
Slide 18: Thank You
')( .~ .. NEOGEN ~ CHEMICALS LTD. A Thank You